CEO William John Miller sold ~$10.8M in open-market sales over two days (Aug 13-17), and CFO John P. Kiernan sold $525K on Aug 10, forming a clear insider selling cluster totaling ~$11.4M. At a $3.1B market cap, this represents ~0.37% — a modest but notable amount, amplified by the CEO's dominant role and the cluster's concentration. The selling is not explained by 10b5-1 patterns or vesting, and the CEO's sales are large in absolute terms, suggesting potential caution ahead of near-term events. The historical calibration shows strong positive alpha on prior VECO calls (avg +5.07% T+20, 60% win rate), but the cluster's net direction is bearish and the proportionality is below the 0.5% threshold for high materiality. The cross-filing actuarial verdicts flag multiple amplifiers (cluster-insider-trades + cluster-press-context, etc.), but no press or earnings context is present in the provided documents, so these are not triggered. The cluster is treated on its standalone merits as a modest bearish signal from top executives, not a transformative event. The historical calibration for score=6 shows p_obs 54% (above 50%) and μ_w +13.4% vs μ_l -17.0% — the net alpha is negative (-3.6% per trade), but the win rate is above 50%, so no downward bias is applied. Score is set at 5 (notable but not significant) given the proportionality and lack of amplifying context. Sentiment is bearish due to the CEO's material open-market sales without a clear liquidity rationale. Key facts: CEO sold ~$10.8M in open-market sales; CFO sold $525K; total cluster value ~$11.4M (0.37% of market cap); no 10b5-1 pattern evident; director gift of 3,000 shares is non-cash and neutral. Actionable insight: Monitor for any upcoming 8-K or press release that could explain the CEO's concentrated selling — if no news emerges within 2 weeks, the selling may be liquidity-driven and less informative. Risks: CEO selling could signal near-term headwinds; cluster may be pre-planned despite no 10b5-1 disclosure; stock has rallied significantly (prior reports show +52% T+20 on one neutral call), so profit-taking is possible. Related tickers: none. Time horizon: days to weeks. Data: netDirection 'selling', totalValue 11400000 (sum of CEO $10.8M + CFO $525K = $11.4M), insiderCount 2, cSuiteCount 2 (CEO and CFO), possibleCatalyst 'null'. Drug names: empty array (not biotech). Cross-filing narrative: no amplifying cross-filing context present — standalone cluster analysis. Confidence: medium (no 10b5-1 plan disclosure, no recent earnings or press release to contextualize).
Price Chart
Executive Summary
CEO William John Miller sold ~$10.8M in open-market sales over two days (Aug 13-17), and CFO John P. Kiernan sold $525K on Aug 10, forming a clear insider selling cluster totaling ~$11.4M. At a $3.1B market cap, this represents ~0.37% — a modest but notable amount, amplified by the CEO's dominant role and the cluster's concentration. The selling is not explained by 10b5-1 patterns or vesting, and the CEO's sales are large in absolute terms, suggesting potential caution ahead of near-term events. The historical calibration shows strong positive alpha on prior VECO calls (avg +5.07% T+20, 60% win rate), but the cluster's net direction is bearish and the proportionality is below the 0.5% threshold for high materiality. The cross-filing actuarial verdicts flag multiple amplifiers (cluster-insider-trades + cluster-press-context, etc.), but no press or earnings context is present in the provided documents, so these are not triggered. The cluster is treated on its standalone merits as a modest bearish signal from top executives, not a transformative event. The historical calibration for score=6 shows p_obs 54% (above 50%) and μ_w +13.4% vs μ_l -17.0% — the net alpha is negative (-3.6% per trade), but the win rate is above 50%, so no downward bias is applied. Score is set at 5 (notable but not significant) given the proportionality and lack of amplifying context. Sentiment is bearish due to the CEO's material open-market sales without a clear liquidity rationale. Key facts: CEO sold ~$10.8M in open-market sales; CFO sold $525K; total cluster value ~$11.4M (0.37% of market cap); no 10b5-1 pattern evident; director gift of 3,000 shares is non-cash and neutral. Actionable insight: Monitor for any upcoming 8-K or press release that could explain the CEO's concentrated selling — if no news emerges within 2 weeks, the selling may be liquidity-driven and less informative. Risks: CEO selling could signal near-term headwinds; cluster may be pre-planned despite no 10b5-1 disclosure; stock has rallied significantly (prior reports show +52% T+20 on one neutral call), so profit-taking is possible. Related tickers: none. Time horizon: days to weeks. Data: netDirection 'selling', totalValue 11400000 (sum of CEO $10.8M + CFO $525K = $11.4M), insiderCount 2, cSuiteCount 2 (CEO and CFO), possibleCatalyst 'null'. Drug names: empty array (not biotech). Cross-filing narrative: no amplifying cross-filing context present — standalone cluster analysis. Confidence: medium (no 10b5-1 plan disclosure, no recent earnings or press release to contextualize).
Financial Impact
Not specified
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-VECO-1787173626263 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Insider Cluster | $47.20 $41.41 | ▼ −12.27% | ▼ −12.27% | $57.38 (+21.57%) |
Jun 11, 2026 16w ago | Institutional Cluster | $71.55 $57.45 | ▲ +19.71% | ▲ +21.60% | $57.38 (+19.80%) |
Jun 10, 2026 16w ago | Insider Cluster | $71.55 $57.45 | ▼ −19.71% | ▼ −21.60% | $57.38 (−19.80%) |
Jun 10, 2026 16w ago | Insider Cluster | $71.55 $57.45 | ▼ −19.71% | ▼ −21.60% | $57.38 (−19.80%) |
May 27, 2026 18w ago | Insider Cluster | $59.13 $70.95 | ▲ +19.99% | ▲ +23.13% | $57.38 (−2.96%) |
May 18, 2026 19w ago | Insider Cluster | $54.69 $75.78 | ▼ −38.56% | ▼ −37.58% | $57.38 (−4.92%) |
May 7, 2026 21w ago | Insider Cluster | $57.72 $60.46 | ▼ −4.75% | ▼ −1.61% | $57.38 (+0.59%) |
May 5, 2026 21w ago | 8-K | $62.01 $60.46 | ▲ +2.50% | ▲ +5.28% | $57.38 (+7.47%) |
Apr 21, 2026 23w ago | Press Release | $50.37 $54.69 | ▲ +8.58% | ▲ +5.41% | $57.38 (+13.92%) |
Mar 19, 2026 28w ago | DEFA14A | $30.65 $46.73 | ▲ +52.46% | ▲ +43.14% | $57.38 (+87.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access